Post-ET Myelofibrosis clinical trials at UCLA
1 research study open to eligible people
Showing trials for
KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF
open to eligible people ages 18 years and up
This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.
Whittier, California and other locations
Our lead scientists for Post-ET Myelofibrosis research studies include Gary Schiller.
Last updated: